TIFFANY SHADRICK: Open Payments
NPI 1609605245 · ENGLEWOOD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$794 in 26 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $270 · 2025 $794
Food & beverage: $695Education: $99
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $246 |
| ADC THERAPEUTICS AMERICA, INC. | 1 | $142 |
| GlaxoSmithKline, LLC. | 3 | $81 |
| Novartis Pharmaceuticals Corporation | 3 | $68 |
| Incyte Corporation | 3 | $60 |
| Celgene Corporation | 2 | $47 |
| Legend Biotech USA Inc. | 1 | $31 |
| TerSera Therapeutics LLC | 1 | $31 |
| Gilead Sciences, Inc. | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
Products named: Xospata, OJJAARA, JAKAFI, REBLOZYL, CARVYKTI, Zoladex, Vyloy, Trodelvy.
Industry payments across CO — which companies pay providers there.
